

POST-TEST

Cases from the Community: Investigators Discuss Available Research Guiding the Selection of Therapy for Patients with Chronic Lymphocytic Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following drug types best reflects the mechanism of action of sonidotoclax?
 - a. Bruton tyrosine kinase (BTK) inhibitor
 - b. Bcl-2 inhibitor**
 - c. PI3K inhibitor
 - d. BTK degrader
2. **Results from the Phase III BRUIN**
CLL-313 study evaluating first-line pirtobrutinib versus bendamustine/rituximab (BR) for patients with treatment-naïve chronic lymphocytic leukemia (CLL) included which efficacy finding?
 - a. No significant difference in progression-free survival (PFS)
 - b. A numerical but nonsignificant improvement in PFS with pirtobrutinib
 - c. A statistically significant improvement in PFS with pirtobrutinib**
3. **Results from the Phase III BRUIN**
CLL-314 study evaluating pirtobrutinib versus ibrutinib for patients with BTK inhibitor-naïve CLL that was either treatment-naïve or pretreated reported which efficacy finding?
 - a. A statistically significant improvement in PFS with pirtobrutinib
 - b. Noninferiority in overall response rate (ORR) with pirtobrutinib in both the pretreated and intent-to-treat populations**
 - c. Noninferiority in ORR with pirtobrutinib in the pretreated population only
4. What was the approximate incidence of Grade ≥ 3 cytokine release syndrome among patients receiving lisocabtagene maraleucel for relapsed/refractory CLL in the Phase I/II TRANSCEND CLL 004 trial?
 - a. Lower than 1%
 - b. Lower than 5%
 - c. Lower than 10%**
 - d. Higher than 10%
5. Which of the following chimeric antigen receptor T-cell therapies is FDA approved for CLL?
 - a. Axicabtagene ciloleucel
 - b. Lisocabtagene maraleucel**
 - c. Tisagenlecleucel
 - e. None of the above